Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +48.10%
#3 Pons Pons +21.27%
#4 Non-Playable Coin Non-Playable Coin +21.00%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +20.47%
#6 ApeX ApeX +20.21%
#7 OriginTrail OriginTrail +20.09%
#8 龙虾 (Lobster) 龙虾 (Lobster) +19.97%
#9 Zora Zora +16.31%
#10 Morpho Morpho +16.16%
Coin of the day
Smilek to the Bank Smilek to the Bank
Settings
Language
ENGLISH
Currency
USD
Theme
BioGend Therapeutics Co., Ltd. BioGend Therapeutics Co., Ltd.

BioGend Therapeutics Co., Ltd.

6733
Rank in Stocks #21371
This company specializes in the development of innovative regenerative... This company specializes in the development of innovative regenerative bio-orthopedic products. Its current pipeline includes BiG-001 and BiG-006, both of which are osteoinductive bone graft substitutes. Additionally, it is advancing BiG-009, an autologous cartilage repair system. Established in 2016, the firm's operations are based in Taipei, Taiwan.
Share Price
$0.81882497
Last synced: 2026-08-21
Market Cap
$108.85M
Change (1 day)
0.39%
Change (1 year)
-38.35%
Country
TW
Trade BioGend Therapeutics Co., Ltd. (6733)

Category

Healthcare
Revenue for BioGend Therapeutics Co., Ltd. (6733)
Revenue in Aug 2026 TTM: 0
According to BioGend Therapeutics Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for BioGend Therapeutics Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH